CLDX$30.09
$29.8967
Chart
Performance
Key Stats
AI CLDX Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
BuyCelldex Therapeutics shows promising growth potential driven by its innovative drug pipeline and strong thematic alignment in the biopharmaceutical sector. While current financial performance indicates significant investment and negative earnings, its balance sheet remains robust. Technical indicators suggest a mixed short-term outlook, but the long-term trend appears positive.
Thematic
Celldex Therapeutics is well-positioned to benefit from major secular growth trends in biotechnology, specifically in addressing unmet needs in inflammatory, allergic, and autoimmune diseases.
Fundamental
Celldex Therapeutics is in a high-investment phase with negative earnings and cash flow from operations. However, it maintains a strong cash position and a low debt level, providing a stable foundation for its ongoing development activities.
Technical
The stock is showing a positive long-term trend, trading above key moving averages. While some oscillators suggest it's approaching overbought levels, the overall momentum appears to be in favor of further upside, with key support levels identified.
| Factor | Score |
|---|---|
| Biopharmaceutical Innovation | 90 |
| Healthcare Demand Growth | 85 |
| Regulatory Landscape | 70 |
| Biotechnology Advancements | 85 |
| Competition | 75 |
| Factor | Score |
|---|---|
| Valuation | 15 |
| Profitability | 10 |
| Growth | 20 |
| Balance Sheet Health | 95 |
| Cash Flow | 10 |
| Factor | Score |
|---|---|
| Trend Analysis | 75 |
| Momentum | 70 |
| Volume Confirmation | 70 |
| Support & Resistance | 75 |
| Short-Term Oscillators | 65 |
AI Investing Checklist
Powered by LiveAIBullish Points (7)
Positive EPS Surprise Trend
The company has exceeded earnings per share (EPS) estimates in the last three consecutive quarters, indicating consistent operational efficiency and better-than-expected profitability.
Undervalued based on P/S Ratio
The Price-to-Sales (P/S) ratio of 222.0 is significantly lower than the industry average of 648.3, suggesting the company might be undervalued relative to its revenue generation.
Bearish Points (7)
Negative Net Income
The company has consistently reported negative net income over the past few years, with a TTM net income of -$143.009 million, raising concerns about long-term profitability.
High Price-to-Sales Ratio
The trailing Price-to-Sales (P/S) ratio of 301.9 is exceptionally high, indicating that the market is pricing in significant future growth that may be difficult to achieve.
Calendar
February 2019
11
Next Dividend Date
August 2025
12
Next Earnings Date
H: $-0.76
A: $-0.84
L: $-0.95
H: 3.00M
A: 1.13M
0Profile
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. Its clinical development programs are Barzolvolimab (CDX-0159), a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity for treating chronic urticarias, prurigo nodularis, eosinophilic esophagitis, and atopic dermatitis; and CDX-622, a bispecific candidate for inflammatory diseases, which targets two complementary pathways that drive chronic inflammation, potently neutralizing the alarmin thymic stromal lymphopoietin and depleting mast cells through stem cell factor starvation. The company is headquartered in Hampton, New Jersey.
Seasonals
Price Target
58.54 USD
The 39 analysts offering 1 year price forecasts for CLDX have a max estimate of 90.00 and a min estimate of 31.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Income Statement
Cash Flow
Related Companies
Powered by LiveAIWeight: 95
Direct competitor in KIT inhibition for mast cell driven diseases (CDX-0159 vs. BPMC's avapritinib), a key focus area for Celldex's clinical pipeline.
Weight: 92
Clinical-stage biotechnology company focused on developing bispecific antibodies and antibody-drug conjugates (ADCs) for oncology, highly aligned with Celldex's core technology and pipeline focus.
Weight: 90
Leading antibody discovery and development company with a significant pipeline in oncology and immunology, including bispecifics, representing a major competitor and innovator in the space.
Weight: 90
Immuno-oncology company developing checkpoint modulators, antibody-drug conjugates (ADCs), and bispecific antibodies, directly overlapping with Celldex's focus areas.